<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Cancer</journal-id><journal-id journal-id-type="iso-abbrev">BMC Cancer</journal-id><journal-title-group><journal-title>BMC Cancer</journal-title></journal-title-group><issn pub-type="epub">1471-2407</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6364416</article-id><article-id pub-id-type="publisher-id">5324</article-id><article-id pub-id-type="doi">10.1186/s12885-019-5324-y</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Increased expression of Ki-67 is a poor prognostic marker for colorectal cancer patients: a meta analysis</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Luo</surname><given-names>Zhao-Wen</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Zhu</surname><given-names>Ming-Gu</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Zhang</surname><given-names>Zhi-Qiao</given-names></name><address><phone>+8675722318693</phone><email>sdgrxjbk@163.com</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Ye</surname><given-names>Feng-Jun</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Huang</surname><given-names>Wen-Heng</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Luo</surname><given-names>Xue-Zhang</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1"><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 8877 7471</institution-id><institution-id institution-id-type="GRID">grid.284723.8</institution-id><institution>Department of Internal Medicine, </institution><institution>The Affiliated Chencun Hospital of Shunde Hospital, Southern Medical University, </institution></institution-wrap>Shunde, 528313 Guangdong China </aff></contrib-group><pub-date pub-type="epub"><day>6</day><month>2</month><year>2019</year></pub-date><pub-date pub-type="pmc-release"><day>6</day><month>2</month><year>2019</year></pub-date><pub-date pub-type="collection"><year>2019</year></pub-date><volume>19</volume><elocation-id>123</elocation-id><history><date date-type="received"><day>22</day><month>3</month><year>2018</year></date><date date-type="accepted"><day>28</day><month>1</month><year>2019</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s). 2019</copyright-statement><license license-type="OpenAccess"><license-p><bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1">The prognostic value of Ki-67 expression in colorectal cancer patients was controversial. Therefore, this meta analysis was conducted to ascertain the prognostic value of Ki-67 expression in colorectal cancer patients.</p></sec><sec><title>Methods</title><p id="Par2">The electronic databases, including EMBASE, PubMed, Cochrane Library and Web of Knowledge database, were searched from January 1970 to July 2017. The pooled hazard ratios and 95% confidence intervals were calculated to evaluate the prognostic value of Ki-67 expression for colorectal cancer patients.</p></sec><sec><title>Results</title><p id="Par3">Totally 34 eligible studies and 6180 colorectal cancer patients were included in the present meta analysis. The pooled hazard ratios were 1.54(95% CI 1.17&#x02013;2.02, <italic>P</italic>&#x02009;=&#x02009;0.005) for overall survival and 1.43(1.12&#x02013;1.83, <italic>P</italic>&#x02009;=&#x02009;0.008) for disease free survival in univariate analysis. After adjustment of other prognostic factors, the pooled HR was 1.50(95% CI 1.02&#x02013;2.22, <italic>P</italic>&#x02009;=&#x02009;0.03) for overall survival in multivariate analysis.</p></sec><sec><title>Conclusion</title><p id="Par4">The present meta analysis demonstrated that high Ki-67 expression is significantly correlated with poor overall survival and disease free survival, indicating that high Ki-67 expression may serve as a valuable predictive method for poor prognosis of colorectal cancer patients.</p></sec></abstract><funding-group><award-group><funding-source><institution>Health Department and Finance Department of Guangdong Province</institution></funding-source><award-id>A2016450</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2019</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par20">Colorectal carcinoma (CRC) is the fourth most common cause of death induced by carcinoma, accounting for 600,000 deaths per year [<xref ref-type="bibr" rid="CR1">1</xref>]. Some clinical factors, such as tumor stage, tumor necrosis, vascular invasion and differentiation, have been reported to be associated with prognosis of CRC patients [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>]. However, these factors were not sufficient to accurately make risk stratification for clinical prognosis. In clinical practice, identification of patients with high risk of poor prognosis would help to optimize treatment and to improve clinical prognosis. Therefore, there is an urgent need to find reliable prognostic factors for prediction of clinical prognosis in CRC patients.</p><p id="Par21">Ki-67 antigen expresses throughout the cell cycle in proliferating cells, except for quiescent (G0) cells [<xref ref-type="bibr" rid="CR4">4</xref>]. The correlation between Ki-67 expression and prognosis of CRC patients were still contradictory in various studies [<xref ref-type="bibr" rid="CR5">5</xref>&#x02013;<xref ref-type="bibr" rid="CR38">38</xref>]. Several studies showed that high Ki-67 expression was related with poor overall survival (OS) [<xref ref-type="bibr" rid="CR26">26</xref>&#x02013;<xref ref-type="bibr" rid="CR30">30</xref>], whereas several studies reported that high Ki-67 expression was correlated with favorable OS [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>]. Therefore, we performed this meta analysis to determine the prognostic value of Ki-67 expression in CRC patients.</p></sec><sec id="Sec2"><title>Materials and methods</title><sec id="Sec3"><title>Literature search strategy</title><p id="Par22">Four electronic databases, including EMBASE, PubMed, Web of Knowledge and Cochrane Library, were searched from January 1990 to July 2017 for eligible studies. We performed literature search by combined text word and MeSH strategy for PubMed with the following search strategy: (&#x0201c;Ki67&#x0201d; or &#x0201c;Ki-67&#x0201d; or &#x0201c;MIB-1&#x0201d; or &#x0201c;MIB1&#x0201d;) and (&#x0201c;carcinoma&#x0201d; or &#x0201c;neoplasm&#x0201d; or &#x0201c;tumor&#x0201d; or &#x0201c;cancer&#x0201d; or &#x0201c;malignancy&#x0201d;) and (&#x0201c;colorectal&#x0201d; or &#x0201c;rectal&#x0201d; or &#x0201c;colon&#x0201d;) and (&#x0201c;prognosis&#x0201d; or &#x0201c;prognostic&#x0201d; or &#x0201c;survival&#x0201d; or &#x0201c;outcome&#x0201d; or &#x0201c;mortality&#x0201d;).The strategies for EMBASE and other databases were similar but were adapted according to the guideline of the database. Meanwhile, expanded search of hyponym was performed. In the retrieval process, we made a manual search using the references of the including articles to supplement eligible studies. We contacted the corresponding author to get necessary study data if necessary. The search was restricted to human studies and there was no restriction in terms of language or publication time. All information investigation and collection were conducted according to the principles of Declaration of Helsinki.</p></sec><sec id="Sec4"><title>Criteria for inclusion and exclusion</title><p id="Par23">The inclusion criteria were defined as follows: (1) proven pathological diagnosis of CRC in humans; (2) assessment of Ki-67 expression by using immunohistochemistry (IHC) method; (3) enough survival information such as hazard ratio (HR) and 95% confidence interval (CI). Studies not directly providing hazard ratio and 95% confidence interval were included if survival information were available from survival curves or tables. Articles published in Chinese were included in the present meta analysis as English literature. For multiple studies from the same study population, only the most recently published study was included in the present analysis.</p><p id="Par24">The following studies were excluded: (1) non-human experiments; (2) case reports, reviews, letters and conference abstracts without survival information; (3) lack of the necessary survival information.</p></sec><sec id="Sec5"><title>Quality assessment</title><p id="Par25">Two reviewers (Zhi-Qiao Zhang and Zhao-Wen Luo) independently assessed the quality of the studies included in the present meta analysis using Newcastle-Ottawa Quality Assessment Scale (NOS). The NOS comprises assessments of patient selection, study comparability, follow-up and outcomes of interest. The total scores were used to evaluate the quality of the study. Disagreements between two reviewers (Zhi-Qiao Zhang and Zhao-Wen Luo) were resolved by consultation with a third reviewer (Ming-Gu Zhu).</p></sec><sec id="Sec6"><title>Data extraction</title><p id="Par26">Two investigators (Zhi-Qiao Zhang and Zhao-Wen Luo) independently extracted the survival information of the original studies: surname of the first author, country, study sample size, publication year, disease stage, test method of Ki-67 expression, clinical parameters, and survival information (HRs and 95%CIs). All study information were extracted and recorded by using a standardized form. All included studies were coded as the surname of the first author + publish year in the standardized form. Study authors were contacted to get necessary data if necessary. Disagreements between two investigators were resolved by discussion with a third investigator (Ming-Gu Zhu).</p></sec><sec id="Sec7"><title>Statistical analysis</title><p id="Par27">The statistical analysis was performed according to the suggestions advised by the Meta analysis of Observational.</p><p id="Par28">Studies in Epidemiology group(MOOSE) [<xref ref-type="bibr" rid="CR39">39</xref>]. The hazard ratios (HR) and 95% CI were used to summary the final effects of survival outcome. We pooled HR and 95% CI if the survival data were reported in the original articles. While HR and 95% CI were not directly reported in the articles, survival data was extracted from Kaplan-Meier curve and used to estimate HR. The heterogeneity among various studies was measured by the Q and <italic>I</italic><sup>2</sup> tests. A probability value of <italic>I</italic><sup>2</sup> value&#x02265;30% and <italic>P</italic> value&#x0003c;&#x02009;0.1 indicated the existence of significant heterogeneity. A random effect model (DerSimonian and Laird method) or fixed effect model(Mantel-Haenszel method) was used according to the results of heterogeneity analyses. Meta-regression analyses (Reml method) and subgroup analyses were performed to explore the sources of heterogeneity. Funnel plot, Begg&#x02019;s test, Egger&#x02019;s test, and trim and fill method were performed to assess publication bias. The difference was considered to be statistically significant if <italic>P</italic> value &#x0003c;&#x02009;0.05. The statistical analyses were performed by STATA version 12.0 software (Stata Corporation, College Station, Texas, USA).</p></sec></sec><sec id="Sec8"><title>Results</title><sec id="Sec9"><title>Search results</title><p id="Par29">The initial search returned a total of 410 articles (with 204 duplicate articles). After screening the abstracts, 159 irrelevant articles were excluded according to the criteria for inclusion and exclusion. Reviewers identified 47 potential studies for full-text review and 13 articles were eliminated due to inadequate data for meta analysis. Finally, a total of 34 studies were included in the present meta analysis [<xref ref-type="bibr" rid="CR5">5</xref>&#x02013;<xref ref-type="bibr" rid="CR38">38</xref>]. The details of screening process were shown in Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>. Quality assessment of 34 eligible studies were performed by using the Newcastle-Ottawa Scale (NOS).<fig id="Fig1"><label>Fig. 1</label><caption><p>Flowchart of study selection in the present meta analysis</p></caption><graphic xlink:href="12885_2019_5324_Fig1_HTML" id="MO1"/></fig></p></sec><sec id="Sec10"><title>Study selection and characteristics</title><p id="Par30">The characteristic of the 34 included studies were summarized in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>. The publication time ranged from 1997 to 2015.The patient number of 34 studies ranged from 30 to 867,with a mean sample size of 182. The mean length of follow-up period ranged from 23 to 130&#x02009;months. The NOS scores for quality of 34 studies in this meta analysis varied from 6 to 7, with a mean value of 6.5. Ki-67 expression were measured in surgical tumor tissues.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Characteristics of studies included in the present meta analysis</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Author/Country/Year</th><th>Detection</th><th>Quantitative</th><th>Antibody</th><th>Fixed</th><th>Positive<sup>a</sup></th><th>Median age</th><th>History</th><th/><th>Cut off</th><th>Patient</th></tr><tr><th>method</th><th>method</th><th>type</th><th>method</th><th>Rate(%)</th><th>(Range)</th><th>Type/ Stage</th><th>Therapy</th><th>Value</th><th>Number</th></tr></thead><tbody><tr><td>Meyer [<xref ref-type="bibr" rid="CR5">5</xref>]<break/>Germany 2009</td><td>microscope</td><td>semi-quantitative</td><td>mouse monoclonal</td><td>formalin</td><td>88.8%</td><td>64(28&#x02013;91)</td><td>CC<break/>II-IV</td><td>S&#x02009;+&#x02009;C</td><td>NR</td><td>392</td></tr><tr><td>Garrity [<xref ref-type="bibr" rid="CR6">6</xref>]<break/>Canada 2004</td><td>NR</td><td>quantitative</td><td>NR</td><td>formalin</td><td>62.4%</td><td>NR</td><td>CRC<break/>II-III</td><td>S&#x02009;+&#x02009;C</td><td>27.0%</td><td>366</td></tr><tr><td>Fodor [<xref ref-type="bibr" rid="CR7">7</xref>]<break/>America 2012</td><td>Tissue microarrays</td><td>quantitative</td><td>NR</td><td>formalin</td><td>52.0%</td><td>71.5(18&#x02013;97)</td><td>CRC<break/>I-IV</td><td>S&#x02009;+&#x02009;C</td><td>60.0%</td><td>867</td></tr><tr><td>Salminen [<xref ref-type="bibr" rid="CR8">8</xref>]<break/>Finland 2005</td><td>microscope</td><td>quantitative</td><td>mouse monoclonal</td><td>formalin</td><td>45.2%</td><td>66(36&#x02013;86)</td><td>RC<break/>I-IV</td><td>S&#x02009;+&#x02009;R</td><td>40.0%</td><td>146</td></tr><tr><td>Zhang [<xref ref-type="bibr" rid="CR9">9</xref>]<break/>China 2015</td><td>Tissue microarrays</td><td>quantitative</td><td>NR</td><td>formalin</td><td>47.9%</td><td>72(37&#x02013;93)</td><td>CRC<break/>I-IV</td><td>S&#x02009;+&#x02009;R</td><td>40.0%</td><td>73</td></tr><tr><td>Yoshimura [<xref ref-type="bibr" rid="CR10">10</xref>]<break/>Japan 2003</td><td>microscope</td><td>quantitative</td><td>monoclonal</td><td>NR</td><td>NR</td><td>65</td><td>CRC<break/>III</td><td>S</td><td>62.0%</td><td>56</td></tr><tr><td>Li [<xref ref-type="bibr" rid="CR11">11</xref>]<break/>China 2010</td><td>Tissue microarrays</td><td>semi-quantitative</td><td>monoclonal</td><td>formalin</td><td>78.8%</td><td>65(22&#x02013;95)</td><td>CC<break/>I-IV</td><td>S</td><td>10.0%</td><td>203</td></tr><tr><td>Li [<xref ref-type="bibr" rid="CR12">12</xref>]<break/>China 2011</td><td>Tissue microarrays</td><td>semi-quantitative</td><td>monoclonal</td><td>formalin</td><td>78.8%</td><td>65(22&#x02013;95)</td><td>CC<break/>I-IV</td><td>S</td><td>10.0%</td><td>203</td></tr><tr><td>Dawson [<xref ref-type="bibr" rid="CR13">13</xref>]<break/>Switzerland 2014</td><td>Tissue microarrays</td><td>quantitative</td><td>monoclonal</td><td>formalin</td><td>NR</td><td>71(35&#x02013;93)</td><td>CRC<break/>I-IV</td><td>S&#x02009;+&#x02009;C</td><td>30.0%</td><td>188</td></tr><tr><td>Weber 2001 [<xref ref-type="bibr" rid="CR14">14</xref>]<break/>France 2001</td><td>microscope</td><td>quantitative</td><td>mouse monoclonal</td><td>formalin</td><td>50.2%</td><td>61(29&#x02013;80)</td><td>CRCLM<break/>I-IV</td><td>S&#x02009;+&#x02009;C</td><td>50.0%</td><td>221</td></tr><tr><td>Xi [<xref ref-type="bibr" rid="CR15">15</xref>]<break/>China 2011</td><td>microscope</td><td>semi-quantitative</td><td>mouse monoclonal</td><td>formalin</td><td>59.7%</td><td>62(20&#x02013;81)</td><td>CRC<break/>I-IV</td><td>S</td><td>score&#x02009;&#x0003e;&#x02009;5</td><td>201</td></tr><tr><td>Ivanecz [<xref ref-type="bibr" rid="CR16">16</xref>]<break/>Slovenia 2014</td><td>microscope</td><td>semi-quantitative</td><td>mouse monoclonal</td><td>formalin</td><td>28.0%</td><td>62(27&#x02013;78)</td><td>CRCLM<break/>I-IV</td><td>S&#x02009;+&#x02009;C</td><td>50.0%</td><td>98</td></tr><tr><td>Rosati [<xref ref-type="bibr" rid="CR17">17</xref>]<break/>Italy 2004</td><td>microscope</td><td>semi-quantitative</td><td>monoclonal</td><td>formalin</td><td>55.3%</td><td>66(29&#x02013;79)</td><td>CRC<break/>II-III</td><td>S&#x02009;+&#x02009;C</td><td>10.0%</td><td>103</td></tr><tr><td>Nishihara [<xref ref-type="bibr" rid="CR18">18</xref>]<break/>Japan 2009</td><td>microscope</td><td>quantitative</td><td>mouse monoclonal</td><td>formalin</td><td>51.2%</td><td>68(33&#x02013;94)</td><td>CRC<break/>I-IV</td><td>S</td><td>40.0%</td><td>201</td></tr><tr><td>Scopa [<xref ref-type="bibr" rid="CR19">19</xref>]<break/>Greece 2003</td><td>microscope</td><td>semi-quantitative</td><td>mouse monoclonal</td><td>NR</td><td>64.0%</td><td>66(25&#x02013;82)</td><td>CRC<break/>I-IV</td><td>S&#x02009;+&#x02009;C</td><td>5.0%</td><td>117</td></tr><tr><td>Visca [<xref ref-type="bibr" rid="CR20">20</xref>]<break/>Italy 1999</td><td>microscope</td><td>semi-quantitative</td><td>mouse monoclonal</td><td>formalin</td><td>90%</td><td>64</td><td>CRC<break/>I-IV</td><td>S</td><td>20.0%</td><td>100</td></tr><tr><td>Handa [<xref ref-type="bibr" rid="CR21">21</xref>]<break/>Japan 1999</td><td>microscope</td><td>quantitative</td><td>monoclonal</td><td>formalin</td><td>65.8%</td><td>66(39&#x02013;90)</td><td>CRC<break/>I-IV</td><td>S</td><td>19.5%</td><td>73</td></tr><tr><td>Bahnassy [<xref ref-type="bibr" rid="CR22">22</xref>]<break/>Egypt 2004</td><td>microscope</td><td>quantitative</td><td>NR</td><td>NR</td><td>NR</td><td>NR</td><td>CRC<break/>I-IV</td><td>S</td><td>11.5%</td><td>60</td></tr><tr><td>Buglioni 1999 [<xref ref-type="bibr" rid="CR23">23</xref>]</td><td>microscope</td><td>quantitative</td><td>NR</td><td>NR</td><td>50.3%</td><td>64(56&#x02013;70)</td><td>CRC<break/>I-IV</td><td>S</td><td>25.0%</td><td>171</td></tr><tr><td>Bertolini [<xref ref-type="bibr" rid="CR24">24</xref>]<break/>Italy 2007</td><td>microscope</td><td>quantitative</td><td>NR</td><td>formalin</td><td>90.0%</td><td>64(26&#x02013;78)</td><td>RC<break/>I-III</td><td>S&#x02009;+&#x02009;C&#x02009;+&#x02009;R</td><td>20.0%</td><td>91</td></tr><tr><td>Kimura [<xref ref-type="bibr" rid="CR25">25</xref>]<break/>Japan 2000</td><td>microscope</td><td>quantitative</td><td>monoclonal</td><td>formalin</td><td>31.0%</td><td>63.1&#x02009;&#x000b1;&#x02009;10.7</td><td>CRC<break/>II-IV</td><td>S</td><td>50.6%</td><td>71</td></tr><tr><td>Fernandez-Cebrian [<xref ref-type="bibr" rid="CR26">26</xref>]<break/>Spain 2007</td><td>microscope</td><td>semi-quantitative</td><td>mouse monoclonal</td><td>NR</td><td>69.1%</td><td>63.9(45&#x02013;96)</td><td>CC<break/>II</td><td>S</td><td>25.0%</td><td>162</td></tr><tr><td>Wu 2012 [<xref ref-type="bibr" rid="CR27">27</xref>]<break/>China 2012</td><td>microscope</td><td>semi-quantitative</td><td>mouse monoclonal</td><td>formalin</td><td>78.7%</td><td>62(22&#x02013;83)</td><td>CRC<break/>I-IV</td><td>S</td><td>score&#x02009;&#x0003e;&#x02009;5</td><td>192</td></tr><tr><td>Furudoi 2001 [<xref ref-type="bibr" rid="CR28">28</xref>]<break/>Japan 2001</td><td>microscope</td><td>quantitative</td><td>monoclonal</td><td>formalin</td><td>45.0%</td><td>63.2&#x02009;&#x000b1;&#x02009;13.9</td><td>CRC<break/>II-IV</td><td>S&#x02009;+&#x02009;C</td><td>47.9%</td><td>111</td></tr><tr><td>Lin [<xref ref-type="bibr" rid="CR29">29</xref>]<break/>China 2008</td><td>microscope</td><td>semi-quantitative</td><td>mouse monoclonal</td><td>NR</td><td>18.3%</td><td>64</td><td>CRC<break/>I-IV</td><td>S</td><td>50.0%</td><td>60</td></tr><tr><td>Hayashi 2015 [<xref ref-type="bibr" rid="CR30">30</xref>]<break/>Japan 2015</td><td>microscope</td><td>quantitative</td><td>mouse monoclonal</td><td>formalin</td><td>63.5%</td><td>65(35&#x02013;83)</td><td>CRCLM<break/>I-IV</td><td>S&#x02009;+&#x02009;C</td><td>30.0%</td><td>54</td></tr><tr><td>Ajani [<xref ref-type="bibr" rid="CR31">31</xref>]<break/>America 2010</td><td>microscope</td><td>quantitative</td><td>monoclonal</td><td>formalin</td><td>50.0%</td><td>NR</td><td>RC<break/>I-IV</td><td>C&#x02009;+&#x02009;R</td><td>median</td><td>30</td></tr><tr><td>Li [<xref ref-type="bibr" rid="CR32">32</xref>]<break/>China 2009</td><td>microscope</td><td>quantitative</td><td>monoclonal</td><td>formalin</td><td>78.8%</td><td>65(22&#x02013;95)</td><td>CC<break/>I-IV</td><td>S</td><td>10.0%</td><td>203</td></tr><tr><td>Hu 2009 [<xref ref-type="bibr" rid="CR33">33</xref>]<break/>China 2009</td><td>microscope</td><td>quantitative</td><td>NR</td><td>formalin</td><td>30.7%</td><td>56.6(34&#x02013;75)</td><td>CRC<break/>NR</td><td>S</td><td>10.0%</td><td>52</td></tr><tr><td>Roxburgh [<xref ref-type="bibr" rid="CR34">34</xref>]<break/>Scotland 2013</td><td>Tissue microarrays</td><td>quantitative</td><td>mouse monoclonal</td><td>NR</td><td>61%</td><td>NR</td><td>CRC<break/>I-III</td><td>S&#x02009;+&#x02009;C</td><td>15%</td><td>230</td></tr><tr><td>Shin 2014 [<xref ref-type="bibr" rid="CR35">35</xref>]<break/>Korea 2014</td><td>microscope</td><td>quantitative</td><td>NR</td><td>NR</td><td>74.4%</td><td>63(30&#x02013;87)</td><td>CRC<break/>I-IV</td><td>S&#x02009;+&#x02009;C</td><td>50.0%</td><td>266</td></tr><tr><td>Nash [<xref ref-type="bibr" rid="CR36">36</xref>]<break/>America 2010</td><td>microscope</td><td>quantitative</td><td>NR</td><td>formalin</td><td>66.0%</td><td>63(19&#x02013;84)</td><td>CRCLM<break/>I-IV</td><td>S&#x02009;+&#x02009;C</td><td>50.0%</td><td>188</td></tr><tr><td>Prall [<xref ref-type="bibr" rid="CR37">37</xref>]<break/>Germany 2004</td><td>Tissue microarrays</td><td>quantitative</td><td>mouse monoclonal</td><td>NR</td><td>50.0%</td><td>64.8(29&#x02013;90)</td><td>CRC<break/>I-IV</td><td>S&#x02009;+&#x02009;C&#x02009;+&#x02009;R</td><td>median</td><td>149</td></tr><tr><td>Zlobec [<xref ref-type="bibr" rid="CR38">38</xref>]<break/>Switzerland 2008</td><td>Tissue microarrays</td><td>quantitative</td><td>NR</td><td>NR</td><td>42.5%</td><td>68.7(36&#x02013;96)</td><td>RC<break/>I-IV</td><td>S&#x02009;+&#x02009;C&#x02009;+&#x02009;R</td><td>15.0%</td><td>482</td></tr></tbody></table><table-wrap-foot><p><italic>NR</italic> not reported, <italic>OS</italic> overall survival, <italic>DFS</italic> disease free survival, <italic>S</italic> surgery, <italic>C</italic> chemotherapy, <italic>R</italic> radiotherapy, <italic>CRC</italic> colorectal cancer, <italic>CRCLM</italic> colorectal liver metastases, <italic>CC</italic> colon cancer, <italic>RC</italic> rectal cancer, <italic>NOS</italic> Newcastle-Ottawa Quality Assessment Scale, <italic>IHC</italic> immunohistochemistry</p><p><sup>a</sup>positive status was defined according to cut off value</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec11"><title>Prognostic value of high Ki-67 expression</title><p id="Par31">Finally 34 studies and 6180 CRC patients were collected and analyzed for prognostic value of Ki-67 expression. The pooled HR was 1.54(95% CI 1.17&#x02013;2.02, <italic>P</italic>&#x02009;=&#x02009;0.005) for overall survival (OS) in univariate analysis (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). After adjustment of other prognostic factors, the pooled HR was 1.50(95% CI 1.02&#x02013;2.22, <italic>P</italic>&#x02009;=&#x02009;0.03) for OS in multivariate analysis (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>). The pooled HR was 1.43(95% CI 1.12&#x02013;1.83, <italic>P</italic>&#x02009;=&#x02009;0.008) for disease survival (DFS) in univariate analysis (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>).<fig id="Fig2"><label>Fig. 2</label><caption><p>Forest plot diagrams of Ki-67 expression for overall survival in univariate analysis</p></caption><graphic xlink:href="12885_2019_5324_Fig2_HTML" id="MO2"/></fig><fig id="Fig3"><label>Fig. 3</label><caption><p>Forest plot diagrams of Ki-67 expression for overall survival in multivariate analysis</p></caption><graphic xlink:href="12885_2019_5324_Fig3_HTML" id="MO3"/></fig><fig id="Fig4"><label>Fig. 4</label><caption><p>Forest plot diagrams of Ki-67 expression for disease free survival in univariate analysis</p></caption><graphic xlink:href="12885_2019_5324_Fig4_HTML" id="MO4"/></fig></p></sec><sec id="Sec12"><title>Publication bias</title><p id="Par32">For OS in univariate analysis, the funnel plot of Ki-67 expression showed obvious asymmetry (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>a), indicating that the pooled results might be influenced by the publication bias. The Begg&#x02019;s test and Egger&#x02019;s test were further performed to explore publication bias in the present meta analysis. There was significant publication bias according to Egger&#x02019;s test (<italic>P</italic>&#x02009;=&#x02009;0.008) whereas Begg&#x02019;s test did not show significant publication bias (<italic>P</italic>&#x02009;=&#x02009;0.629).<fig id="Fig5"><label>Fig. 5</label><caption><p>Funnel plot of high Ki-67 expression. <bold>a</bold> Overall survival in univariate analysis; <bold>b</bold> Overall survival in multivariate analysis; <bold>c</bold> Disease free survival in univariate analysis</p></caption><graphic xlink:href="12885_2019_5324_Fig5_HTML" id="MO5"/></fig></p><p id="Par33">For OS in multivariate analysis, the funnel plot of Ki-67 expression did not show obvious asymmetry (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>b). There was no significant publication bias according to Egger&#x02019;s test (<italic>P</italic>&#x02009;=&#x02009;0.378) and Begg&#x02019;s test (<italic>P</italic>&#x02009;=&#x02009;1.0).</p><p id="Par34">For DFS in univariate analysis, the funnel plot of Ki-67 expression showed obvious asymmetry (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>c). There was significant publication bias according to Egger&#x02019;s test (<italic>P</italic>&#x02009;=&#x02009;0.032) whereas Begg&#x02019;s test did not show significant publication bias in the present study (<italic>P</italic>&#x02009;=&#x02009;0.246).</p></sec><sec id="Sec13"><title>Contour-enhanced funnel plot</title><p id="Par35">The contour-enhanced funnel plot can help to ascertain whether funnel plot asymmetry due to publication bias [<xref ref-type="bibr" rid="CR40">40</xref>]. Contour lines which indicated conventional milestones in levels of statistical significance (0.05, and 0.1) are added to funnel plots. If the dummy studies lie in areas of statistical nonsignificance, then this provides evidence of the possibility that the funnel plot asymmetry is due to publication bias. Conversely, if the dummy studies are in areas of high statistical significance(<italic>P</italic>&#x02009;&#x0003e;&#x02009;0.05), this will support that the cause of the funnel plot asymmetry may be caused by factors other than publication bias, such as poor methodological quality or true heterogeneity.</p><p id="Par36">To explore the potential causes of funnel plot asymmetry for OS in univariate analysis, a contour-enhanced funnel plot by using the trim-and-fill method was performed. The dummy studies were indicated by red triangles and the genuine studies were indicated by green dots (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>). This trim-and-fill method added 9 dummy studies to balance the funnel plot and all 9 dummy studies were in areas of high statistical significance, suggesting that the publication bias might not the major cause of funnel plot asymmetry in the present meta analysis.<fig id="Fig6"><label>Fig. 6</label><caption><p>Contour-enhanced funnel plot for overall survival in univariate analysis</p></caption><graphic xlink:href="12885_2019_5324_Fig6_HTML" id="MO6"/></fig></p></sec><sec id="Sec14"><title>Meta-regression analysis and subgroup analysis</title><p id="Par37">Subgroup analysis (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>) suggested that cut off value, treatment and pathologic type might contribute to the clinical heterogeneity. The pooled HRs were 0.743 (95% CI 0.332&#x02013;1.662, <italic>I</italic><sup>2</sup>&#x02009;=&#x02009;20.7%, <italic>P</italic>&#x02009;=&#x02009;0.261) for rectal cancer (RC) patients and 1.902(0.695&#x02013;5.198, <italic>I</italic><sup>2</sup>&#x02009;=&#x02009;92%, <italic>P</italic>&#x02009;=&#x02009;0.001) for colorectal liver metastases (CRCLM) patients. Further meta- regression analysis did not find any significant source of heterogeneity (all <italic>P</italic>&#x02009;&#x0003e;&#x02009;0.05).<table-wrap id="Tab2"><label>Table 2</label><caption><p>Subgroup analysis for association between Ki-67 expression and overall survival</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Term</th><th>Subgroup</th><th>Number</th><th>Pooled</th><th>95%CI</th><th>
<italic>P</italic>
</th><th>Heterogeneity</th><th>
<italic>P</italic>
</th></tr><tr><th/><th>of study</th><th>HR</th><th/><th/><th>
<italic>I</italic>
<sup><italic>2</italic></sup>
</th><th/></tr></thead><tbody><tr><td rowspan="2">Location</td><td>Asian</td><td>10</td><td>1.89</td><td>1.23&#x02013;2.90</td><td>0.003</td><td>70.9</td><td>0.001</td></tr><tr><td>Non- Asian</td><td>11</td><td>1.282</td><td>0.936&#x02013;1.758</td><td>0.122</td><td>77.4</td><td>0.001</td></tr><tr><td rowspan="2">Cut off value</td><td>&#x02265;40%</td><td>9</td><td>1.5</td><td>1.01&#x02013;2.24</td><td>0.044</td><td>84.9</td><td>0.001</td></tr><tr><td>&#x0003c;40%</td><td>10</td><td>1.71</td><td>1.33&#x02013;2.21</td><td>0.001</td><td>0</td><td>0.529</td></tr><tr><td rowspan="2">Patient number</td><td>&#x02265;100</td><td>13</td><td>1.381</td><td>0.994&#x02013;1.918</td><td>0.054</td><td>75.7</td><td>0.001</td></tr><tr><td>&#x0003c;100</td><td>8</td><td>2.008</td><td>1.131&#x02013;3.564</td><td>0.017</td><td>79.4</td><td>0.001</td></tr><tr><td rowspan="2">Positive rate<sup>a</sup></td><td>&#x02265;50%</td><td>14</td><td>1.513</td><td>1.119&#x02013;2.046</td><td>0.007</td><td>64.2</td><td>0.001</td></tr><tr><td>&#x0003c;50%</td><td>6</td><td>1.589</td><td>0.911&#x02013;2.773</td><td>0.103</td><td>86.5</td><td>0.001</td></tr><tr><td rowspan="4">Pathologic type</td><td>CRC</td><td>14</td><td>1.526</td><td>1.135&#x02013;2.05</td><td>0.005</td><td>62.8</td><td>0.001</td></tr><tr><td>CC</td><td>2</td><td>2.257</td><td>1.418&#x02013;3.594</td><td>0.001</td><td>77.7</td><td>0.001</td></tr><tr><td>RC</td><td>2</td><td>0.743</td><td>0.332&#x02013;1.662</td><td>0.469</td><td>20.7</td><td>0.261</td></tr><tr><td>CRCLM</td><td>3</td><td>1.902</td><td>0.696&#x02013;5.198</td><td>0.21</td><td>92.6</td><td>0.001</td></tr><tr><td rowspan="3">Treatment</td><td>S</td><td>12</td><td>1.518</td><td>1.038&#x02013;2.221</td><td>0.031</td><td>74.6</td><td>0.001</td></tr><tr><td>S&#x02009;+&#x02009;C</td><td>7</td><td>1.477</td><td>0.933&#x02013;2.338</td><td>0.096</td><td>82.3</td><td>0.001</td></tr><tr><td>S&#x02009;+&#x02009;C&#x02009;+&#x02009;R</td><td>2</td><td>2.216</td><td>1.227&#x02013;4.002</td><td>0.008</td><td>0</td><td>0.945</td></tr><tr><td rowspan="2">Extraction method</td><td>Curve</td><td>7</td><td>1.261</td><td>0.915&#x02013;1.736</td><td>0.001</td><td>57.3</td><td>0.029</td></tr><tr><td>Reported</td><td>14</td><td>2.095</td><td>1.491&#x02013;2.02</td><td>0.156</td><td>72.5</td><td>0.001</td></tr></tbody></table><table-wrap-foot><p><italic>HR</italic> hazard ratio, <italic>CI</italic> confidence interval, <italic>CRC</italic> colorectal cancer, <italic>CRCLM</italic> colorectal liver metastases, <italic>CC</italic> colon cancer, <italic>RC</italic> rectal cancer, <italic>S</italic> surgery, <italic>C</italic> chemotherapy, <italic>R</italic> radiotherapy</p><p><sup>a</sup>positive status was defined according to cut off value</p></table-wrap-foot></table-wrap></p><p id="Par38">According to the results of subgroup analysis, we further explored the association between Ki-67 expression and overall survival with different cut off values (Fig.&#x000a0;<xref rid="Fig7" ref-type="fig">7</xref>). The pooled HR (1.97, 95% CI 1.37&#x02013;2.83) in group with cut off value (20&#x02013;30%) was significantly higher than that in other groups, indicating that cut off value (20&#x02013;30%) might be more suitable for clinical practice than other cut off values.<fig id="Fig7"><label>Fig. 7</label><caption><p>Forest plot diagrams of Ki-67 expression for overall survival according different cut off values. <bold>a</bold> Cut off value (5&#x02013;19%); <bold>b</bold> Cut off value (20&#x02013;30%); <bold>c</bold> Cut off value (40&#x02013;49%); <bold>d</bold> Cut off value (50&#x02013;60%)</p></caption><graphic xlink:href="12885_2019_5324_Fig7_HTML" id="MO7"/></fig></p></sec><sec id="Sec15"><title>Sensitivity analyses</title><p id="Par39">All studies were sequentially removed to explore that whether any individual study had a significant influence to the pooled HRs. The pooled HRs of sensitivity meta analysis ranged from 1.49(95%CI: 1.13&#x02013;1.96) to 1.65 (95%CI: 1.26&#x02013;2.15) for OS in univariate analysis, demonstrating that the pooled HRs were not significantly affected by any individual study (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>).<table-wrap id="Tab3"><label>Table 3</label><caption><p>Effect of individual studies on the pooled hazard ratios of Ki-67 expression for overall survival</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Study omitted</th><th>HR</th><th>Lower value of 95% CI</th><th>Upper value of 95% CI</th></tr></thead><tbody><tr><td>1</td><td>1.6470636</td><td>1.2618686</td><td>2.1498425</td></tr><tr><td>2</td><td>1.6286341</td><td>1.2338984</td><td>2.1496494</td></tr><tr><td>3</td><td>1.6086709</td><td>1.2262427</td><td>2.110367</td></tr><tr><td>4</td><td>1.5804045</td><td>1.1893544</td><td>2.1000286</td></tr><tr><td>5</td><td>1.5853532</td><td>1.1829669</td><td>2.1246113</td></tr><tr><td>6</td><td>1.5744233</td><td>1.1822454</td><td>2.0966956</td></tr><tr><td>7</td><td>1.5586835</td><td>1.1753646</td><td>2.0670133</td></tr><tr><td>8</td><td>1.5452128</td><td>1.1628222</td><td>2.0533514</td></tr><tr><td>9</td><td>1.5309644</td><td>1.158212</td><td>2.0236814</td></tr><tr><td>10</td><td>1.5309644</td><td>1.158212</td><td>2.0236814</td></tr><tr><td>11</td><td>1.5234994</td><td>1.150002</td><td>2.0183012</td></tr><tr><td>12</td><td>1.5333095</td><td>1.1640916</td><td>2.0196332</td></tr><tr><td>13</td><td>1.5163125</td><td>1.145869</td><td>2.0065153</td></tr><tr><td>14</td><td>1.5121837</td><td>1.1424872</td><td>2.00151</td></tr><tr><td>15</td><td>1.5081896</td><td>1.1403373</td><td>1.9947045</td></tr><tr><td>16</td><td>1.5015592</td><td>1.136433</td><td>1.9839972</td></tr><tr><td>17</td><td>1.5038622</td><td>1.1387317</td><td>1.9860705</td></tr><tr><td>18</td><td>1.4894764</td><td>1.1326977</td><td>1.9586338</td></tr><tr><td>19</td><td>1.4916791</td><td>1.1332084</td><td>1.9635456</td></tr><tr><td>20</td><td>1.4770394</td><td>1.1257362</td><td>1.9379722</td></tr><tr><td>21</td><td>1.4908768</td><td>1.1371239</td><td>1.9546804</td></tr><tr><td>Combined</td><td>1.5392004</td><td>1.1725948</td><td>2.0204233</td></tr></tbody></table><table-wrap-foot><p><italic>HR</italic> hazard ratio, <italic>CI</italic> confidence interval</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec16"><title>Cumulative meta analysis of Ki-67 expression</title><p id="Par40">We further performed cumulative meta analysis to assess the stability of Ki-67 expression for OS in univariate analysis (Fig.&#x000a0;<xref rid="Fig8" ref-type="fig">8</xref>a), OS in multivariate analysis (Fig.&#x000a0;<xref rid="Fig8" ref-type="fig">8</xref>b) and DFS in univariate analysis (Fig.&#x000a0;<xref rid="Fig8" ref-type="fig">8</xref>c). The pooled HRs of cumulative meta analysis ranged from 1.48(95%CI 1.1&#x02013;2.0) to 2.14 (95%CI 1.64&#x02013;2.79) for OS in univariate analysis since 1999, demonstrating that performance of Ki-67 expression for OS in CRC patients was stable and reliable.<fig id="Fig8"><label>Fig. 8</label><caption><p>Cumulative meta analysis of Ki-67 expression. <bold>a</bold> Overall survival in univariate analysis; <bold>b</bold> Overall survival in multivariate analysis; <bold>c</bold> Disease free survival in univariate analysis</p></caption><graphic xlink:href="12885_2019_5324_Fig8_HTML" id="MO8"/></fig></p></sec></sec><sec id="Sec17"><title>Discussion</title><p id="Par41">The present meta analysis showed that high Ki-67 expression is significantly correlated with poor prognosis in CRC patients. The pooled hazard ratios were 1.54(95% CI 1.17&#x02013;2.02, <italic>P</italic>&#x02009;=&#x02009;0.005) for overall survival and 1.43(1.12&#x02013;1.83, <italic>P</italic>&#x02009;=&#x02009;0.008) for disease free survival in univariate analysis. After adjustment of other prognostic factors, the pooled HR was 1.50(95% CI 1.02&#x02013;2.22, <italic>P</italic>&#x02009;=&#x02009;0.03) for overall survival in multivariate analysis.</p><p id="Par42">Some previous studies have reported that high Ki-67 expression significantly predicted poor OS in CRC patients [<xref ref-type="bibr" rid="CR26">26</xref>&#x02013;<xref ref-type="bibr" rid="CR30">30</xref>]. The conclusion of the present meta analysis was consistent with that of these previous studies. Although the mechanism of Ki-67 expression on tumor prognosis was still uncertain, some clinical studies have provided interesting evidences for utility of Ki-67 expression as a predictive tool for clinical prognosis in patients with different tumors, for example prostate cancer, thyroid carcinoma and renal clear cell [<xref ref-type="bibr" rid="CR41">41</xref>&#x02013;<xref ref-type="bibr" rid="CR43">43</xref>]. Interestingly, there were three studies indicated that there was a negative association between the high Ki-67 expression and the overall survival of CRC patients. Salminen et al. [<xref ref-type="bibr" rid="CR8">8</xref>] reported that HR of high Ki-67 expression was 0.63 (95% CI 0.41&#x02013;0.98) for overall survival in univariate analysis, whereas it was 1.26 (95% CI 0.67&#x02013;2.39) for overall survival in multivariate analysis. Xi et al. [<xref ref-type="bibr" rid="CR15">15</xref>] reported that HR of high Ki-67 expression was 0.34 (95% CI 0.16&#x02013;0.73) for overall survival by using a special scoring system of Ki-67 expression: The intensity of positivity was scored as follows: 0, negative; 1, weak; 2, moderate; 3, strong. The extent of positivity was scored according to the percentage of cells showing positive staining: 0, &#x0003c;&#x02009;5%; 1, 5&#x02013;25%; 2, 25&#x02013;50%; 3, 50&#x02013;75%; 4, &#x0003e;&#x02009;75%. The final score was determined by multiplying the intensity of positivity and the extent of positivity scores and final score&#x02009;&#x0003e;&#x02009;5 was defined as positive. Ivanecz et al. [<xref ref-type="bibr" rid="CR16">16</xref>] selected 98 patients for prognostic study from 406 patients by using the following criteria: first liver resection for CLM; potentially curative R0 resection; follow-up period of surviving patients &#x0003e;&#x02009;5&#x02009;years. The special inclusion criteria might influence the baseline characteristics and weaken the credibility of study conclusion.</p><p id="Par43">There was significant heterogeneity in the present meta analysis. The current meta analysis might exist several potential sources of heterogeneity as follows: First, the heterogeneity caused by different cut off values of Ki-67 expression was inevitable. The subgroup analysis have revealed the influence of different cut off values on heterogeneity. Second, the subgroup analysis suggested that different treatment has a significant effect on heterogeneity and might be a potential source of heterogeneity. Third, obvious difference of the pooled HRs between rectal cancer subgroup and colorectal liver metastases subgroup suggested that further study is need to clarify the exact influence of different pathologic type on clinical prognosis.</p><p id="Par44">Publication bias is an important influence factor for interpreting the conclusion. The funnel plot for OS in univariate analysis was obviously asymmetrical and Egger&#x02019;s test also demonstrated significant publication bias (<italic>P</italic>&#x02009;=&#x02009;0.008). The funnel plot asymmetry might be caused by different reasons as follows: Firstly, publication bias was one important source of funnel plot asymmetry, for example location bias, citation bias, language bias, time lag bias, multiple publication bias and outcome reporting bias. Secondly, the true heterogeneity in intervention effects might be one resource of funnel plot asymmetry. The true heterogeneity might be caused by differences in the intensity of interventions or differences in underlying risk between studies with different sizes. Thirdly, poor methodological quality was another source of funnel plot asymmetry. Smaller studies were often performed with poorer methodological quality than larger studies. Therefore, smaller studies with poorer methodological quality also tended to display larger influences than larger studies. Finally, funnel plot asymmetrical might be caused by chance. We conducted a contour-enhanced funnel plot using the trim-and-fill method to explore the potential cause of funnel plot asymmetry. Given that all 9 dummy studies were in areas of high statistical significance, the publication bias might not the major cause of funnel plot asymmetry in the present meta analysis.</p><p id="Par45">Although significant heterogeneity existed in the present meta analysis, sensitivity analysis demonstrated that the relation between high Ki-67 expression and poor prognosis of CRC patients did not changed after removing any individual study. Meanwhile, cumulative meta analysis also showed that performance of high Ki-67 expression for poor prognosis in CRC patients was stable and reliable.</p><p id="Par46">The present meta analysis had several strengths: Firstly, there were 34 eligible studies and 6180 CRC patients in the present study, which could significantly increase persuasiveness of the conclusion. Secondly, Ki-67 expression in 34 eligible studies was all measured with IHC method, leading to less clinical heterogeneity. Thirdly, studies published in Chinese were also included in this meta analysis as English literature, increasing the representation of the study population.</p><p id="Par47">The conclusion of the present meta analysis should be interpreted cautiously for reasons as follows: Firstly, most studies defined positive status of Ki-67 expression according to different cut off values, which might result in clinical heterogeneity. Hence, it is necessary to determine an universal cut off value for future studies. Secondly, heterogeneity was inevitable due to different baseline characteristics, such as tumor stage and treatment, which might increase clinical heterogeneity and reduce the persuasiveness of the conclusion. Thirdly, some survival data were extracted from survival curves indirectly. Although the method for extracting HR and 95% CI from survival curves is widely accepted, we could not completely eliminate the sources of information inaccuracy in the process of information extraction. Fourthly, Ki-67 expression in the selected studies was measured by IHC method. This method might suffer from important variation among different studies and was not enough precise for a rigorous and precise conclusion. Fifthly, several genes have been reported to be related with the prognosis of CRC patients including KRAS, Cyclin-dependent kinase 2 (cdc2), and Cathepsin D [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR36">36</xref>]. Interestingly enough, Nash reported that patients with KRAS mutant tumors that expressed high levels of Ki-67 had significantly worse DFS than patients with KRAS wild-type tumors that expressed low level of Ki-67, indicating that combined application of these predictive genes might provide more valuable prognostic information and further improve the clinical prediction of prognosis for CRC patients.</p><p id="Par48">In conclusion, the present meta analysis demonstrated that high Ki-67 expression significantly predicts poor overall survival and disease free survival. High Ki-67 expression may serve as a valuable predictive biomarker for poor prognosis in CRC patients.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>C</term><def><p id="Par5">Chemotherapy</p></def></def-item><def-item><term>CC</term><def><p id="Par6">Colon cancer</p></def></def-item><def-item><term>CI</term><def><p id="Par7">Confidence interval</p></def></def-item><def-item><term>CRC</term><def><p id="Par8">Colorectal cancer</p></def></def-item><def-item><term>CRCLM</term><def><p id="Par9">Colorectal liver metastases</p></def></def-item><def-item><term>DFS</term><def><p id="Par10">Disease free survival</p></def></def-item><def-item><term>HR</term><def><p id="Par11">Hazard ratio</p></def></def-item><def-item><term>IHC</term><def><p id="Par12">Immunohistochemistry</p></def></def-item><def-item><term>NOS</term><def><p id="Par13">Newcastle-Ottawa Quality Assessment Scale</p></def></def-item><def-item><term>NR</term><def><p id="Par14">Not reported</p></def></def-item><def-item><term>OR</term><def><p id="Par15">Odds ratio</p></def></def-item><def-item><term>OS</term><def><p id="Par16">Overall survival</p></def></def-item><def-item><term>R</term><def><p id="Par17">Radiotherapy</p></def></def-item><def-item><term>RC</term><def><p id="Par18">Rectal cancer</p></def></def-item><def-item><term>S</term><def><p id="Par19">Surgery</p></def></def-item></def-list></glossary><ack><p>This study was funded by Guangdong Provincial Health Department (No: A2016450). The following URL is the web link of Guangdong Provincial Health Department (<ext-link ext-link-type="uri" xlink:href="http://www.gdwst.gov.cn/">http://www.gdwst.gov.cn/</ext-link>).</p><sec id="FPar1"><title>Funding</title><p id="Par49">This study was funded by Health Department and Finance Department of Guangdong Province. The Grant Number was No: A2016450.The funding account was RMB 5000. The funder had no role in design, data collection, data analysis and publish of the present manuscript.</p></sec><sec id="FPar2" sec-type="data-availability"><title>Availability of data and materials</title><p id="Par50">The datasets supporting the conclusions of the present study were included in the article.</p></sec></ack><notes notes-type="author-contribution"><title>Authors&#x02019; contributions</title><p>ZZ, ZM and LZ designed the study. ZZ, YF, HW, LX, and LZ performed the research; ZZ and ZM collected and analyzed the data; ZZ and ZM wrote the paper; LZ amended the article. ZZ act as the submission&#x02019;s guarantor and takes responsibility for the integrity of the work as a whole, from inception to published article. All authors reviewed the manuscript. All authors read and approved the final manuscript.</p></notes><notes notes-type="COI-statement"><sec id="FPar3"><title>Ethics approval and consent to participate</title><p>Not applicable.</p></sec><sec id="FPar4"><title>Consent for publication</title><p>All the authors have agreed to publish article in the current magazine.</p></sec><sec id="FPar5"><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec id="FPar6"><title>Publisher&#x02019;s Note</title><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></sec></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferlay</surname><given-names>J</given-names></name><name><surname>Soerjomataram</surname><given-names>I</given-names></name><name><surname>Dikshit</surname><given-names>R</given-names></name><name><surname>Eser</surname><given-names>S</given-names></name><name><surname>Mathers</surname><given-names>C</given-names></name><name><surname>Rebelo</surname><given-names>M</given-names></name><name><surname>Parkin</surname><given-names>DM</given-names></name><name><surname>Forman</surname><given-names>D</given-names></name><name><surname>Bray</surname><given-names>F</given-names></name></person-group><article-title>Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012</article-title><source>Int J Cancer</source><year>2015</year><volume>136</volume><fpage>359</fpage><lpage>386</lpage></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huh</surname><given-names>JW</given-names></name><name><surname>Lee</surname><given-names>JH</given-names></name><name><surname>Kim</surname><given-names>HR</given-names></name></person-group><article-title>Expression of p16, p53, and Ki-67 in colorectal adenocarcinoma: a study of 356 surgically resected cases</article-title><source>Hepato-Gastroenterology</source><year>2010</year><volume>57</volume><fpage>734</fpage><lpage>740</lpage><?supplied-pmid 21033219?><pub-id pub-id-type="pmid">21033219</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sheehan</surname><given-names>KM</given-names></name><name><surname>Sheahan</surname><given-names>K</given-names></name><name><surname>O'Donoghue</surname><given-names>DP</given-names></name><name><surname>MacSweeney</surname><given-names>F</given-names></name><name><surname>Conroy</surname><given-names>RM</given-names></name><name><surname>Fitzgerald</surname><given-names>DJ</given-names></name><name><surname>Murray</surname><given-names>FE</given-names></name></person-group><article-title>The relationship between cyclooxygenase-2 expression and colorectal cancer</article-title><source>JAMA</source><year>1999</year><volume>282</volume><fpage>1254</fpage><lpage>1257</lpage><?supplied-pmid 10517428?><pub-id pub-id-type="pmid">10517428</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schluter</surname><given-names>C</given-names></name><name><surname>Duchrow</surname><given-names>M</given-names></name><name><surname>Wohlenberg</surname><given-names>C</given-names></name><name><surname>Becker</surname><given-names>MH</given-names></name><name><surname>Key</surname><given-names>G</given-names></name><name><surname>Flad</surname><given-names>HD</given-names></name><name><surname>Gerdes</surname><given-names>J</given-names></name></person-group><article-title>The cell proliferation-associated antigen of antibody Ki-67: a very large, ubiquitous nuclear protein with numerous repeated elements, representing a new kind of cell cycle-maintaining proteins</article-title><source>J Cell Biol</source><year>1993</year><volume>123</volume><issue>3</issue><fpage>513</fpage><lpage>522</lpage><pub-id pub-id-type="pmid">8227122</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meyer</surname><given-names>A</given-names></name><name><surname>Merkel</surname><given-names>S</given-names></name><name><surname>Bruckl</surname><given-names>W</given-names></name><name><surname>Schellerer</surname><given-names>V</given-names></name><name><surname>Schildberg</surname><given-names>C</given-names></name><name><surname>Campean</surname><given-names>V</given-names></name><name><surname>Hohenberger</surname><given-names>W</given-names></name><name><surname>Croner</surname><given-names>RS</given-names></name></person-group><article-title>Cdc2 as prognostic marker in stage UICC II colon carcinomas</article-title><source>Eur J Cancer</source><year>2009</year><volume>45</volume><issue>8</issue><fpage>1466</fpage><lpage>1473</lpage><?supplied-pmid 19223178?><pub-id pub-id-type="pmid">19223178</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garrity</surname><given-names>MM</given-names></name><name><surname>Burgart</surname><given-names>LJ</given-names></name><name><surname>Mahoney</surname><given-names>MR</given-names></name><name><surname>Windschitl</surname><given-names>HE</given-names></name><name><surname>Salim</surname><given-names>M</given-names></name><name><surname>Wiesenfeld</surname><given-names>M</given-names></name><name><surname>Krook</surname><given-names>JE</given-names></name><name><surname>Michalak</surname><given-names>JC</given-names></name><name><surname>Goldberg</surname><given-names>RM</given-names></name><name><surname>O'Connell</surname><given-names>MJ</given-names></name><etal/></person-group><article-title>Prognostic value of proliferation, apoptosis, defective DNA mismatch repair, and p53 overexpression in patients with resected Dukes' B2 or C colon cancer: a north central Cancer treatment group study</article-title><source>J Clin Oncol</source><year>2004</year><volume>22</volume><issue>9</issue><fpage>1572</fpage><lpage>1582</lpage><?supplied-pmid 15117979?><pub-id pub-id-type="pmid">15117979</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fodor</surname><given-names>IK</given-names></name><name><surname>Hutchins</surname><given-names>GG</given-names></name><name><surname>Espiritu</surname><given-names>C</given-names></name><name><surname>Quirke</surname><given-names>P</given-names></name><name><surname>Jubb</surname><given-names>AM</given-names></name></person-group><article-title>Prognostic and predictive significance of proliferation in 867 colorectal cancers</article-title><source>J Clin Pathol</source><year>2012</year><volume>65</volume><issue>11</issue><fpage>989</fpage><lpage>995</lpage><?supplied-pmid 22859394?><pub-id pub-id-type="pmid">22859394</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salminen</surname><given-names>E</given-names></name><name><surname>Palmu</surname><given-names>S</given-names></name><name><surname>Vahlberg</surname><given-names>T</given-names></name><name><surname>Roberts</surname><given-names>PJ</given-names></name><name><surname>Soderstrom</surname><given-names>KO</given-names></name></person-group><article-title>Increased proliferation activity measured by immunoreactive Ki67 is associated with survival improvement in rectal/recto sigmoid cancer</article-title><source>World J Gastroenterol</source><year>2005</year><volume>11</volume><issue>21</issue><fpage>3245</fpage><lpage>3249</lpage><?supplied-pmid 15929175?><pub-id pub-id-type="pmid">15929175</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Zhou</surname><given-names>L</given-names></name><name><surname>Feng</surname><given-names>X</given-names></name><name><surname>Cheng</surname><given-names>J</given-names></name><name><surname>Yu</surname><given-names>Y</given-names></name><name><surname>Gong</surname><given-names>Y</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Tian</surname><given-names>L</given-names></name><etal/></person-group><article-title>Increased HMGB1 and cleaved caspase-3 stimulate the proliferation of tumor cells and are correlated with the poor prognosis in colorectal cancer</article-title><source>J Exp Clin Cancer Res</source><year>2015</year><volume>34</volume><fpage>51</fpage><?supplied-pmid 25986235?><pub-id pub-id-type="pmid">25986235</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoshimura</surname><given-names>H</given-names></name><name><surname>Dhar</surname><given-names>DK</given-names></name><name><surname>Nakamoto</surname><given-names>T</given-names></name><name><surname>Kotoh</surname><given-names>T</given-names></name><name><surname>Takano</surname><given-names>M</given-names></name><name><surname>Soma</surname><given-names>G</given-names></name><name><surname>Nagasue</surname><given-names>N</given-names></name></person-group><article-title>Prognostic significance of tumor necrosis factor receptor in colorectal adenocarcinoma</article-title><source>Anticancer Res</source><year>2003</year><volume>23</volume><issue>1A</issue><fpage>85</fpage><lpage>89</lpage><?supplied-pmid 12680198?><pub-id pub-id-type="pmid">12680198</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>DW</given-names></name><name><surname>Tang</surname><given-names>HM</given-names></name><name><surname>Fan</surname><given-names>JW</given-names></name><name><surname>Yan</surname><given-names>DW</given-names></name><name><surname>Zhou</surname><given-names>CZ</given-names></name><name><surname>Li</surname><given-names>SX</given-names></name><name><surname>Wang</surname><given-names>XL</given-names></name><name><surname>Peng</surname><given-names>ZH</given-names></name></person-group><article-title>Expression level of Bmi-1 oncoprotein is associated with progression and prognosis in colon cancer</article-title><source>J Cancer Res Clin Oncol</source><year>2010</year><volume>136</volume><issue>7</issue><fpage>997</fpage><lpage>1006</lpage><?supplied-pmid 20024662?><pub-id pub-id-type="pmid">20024662</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>D</given-names></name><name><surname>Peng</surname><given-names>X</given-names></name><name><surname>Yan</surname><given-names>D</given-names></name><name><surname>Tang</surname><given-names>H</given-names></name><name><surname>Huang</surname><given-names>F</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Peng</surname><given-names>Z</given-names></name></person-group><article-title>Msi-1 is a predictor of survival and a novel therapeutic target in colon cancer</article-title><source>Ann Surg Oncol</source><year>2011</year><volume>18</volume><issue>7</issue><fpage>2074</fpage><lpage>2083</lpage><?supplied-pmid 21442350?><pub-id pub-id-type="pmid">21442350</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dawson</surname><given-names>H</given-names></name><name><surname>Koelzer</surname><given-names>VH</given-names></name><name><surname>Karamitopoulou</surname><given-names>E</given-names></name><name><surname>Economou</surname><given-names>M</given-names></name><name><surname>Hammer</surname><given-names>C</given-names></name><name><surname>Muller</surname><given-names>DE</given-names></name><name><surname>Lugli</surname><given-names>A</given-names></name><name><surname>Zlobec</surname><given-names>I</given-names></name></person-group><article-title>The apoptotic and proliferation rate of tumour budding cells in colorectal cancer outlines a heterogeneous population of cells with various impacts on clinical outcome</article-title><source>Histopathology</source><year>2014</year><volume>64</volume><issue>4</issue><fpage>577</fpage><lpage>584</lpage><?supplied-pmid 24111856?><pub-id pub-id-type="pmid">24111856</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weber</surname><given-names>JC</given-names></name><name><surname>Nakano</surname><given-names>H</given-names></name><name><surname>Bachellier</surname><given-names>P</given-names></name><name><surname>Oussoultzoglou</surname><given-names>E</given-names></name><name><surname>Inoue</surname><given-names>K</given-names></name><name><surname>Shimura</surname><given-names>H</given-names></name><name><surname>Wolf</surname><given-names>P</given-names></name><name><surname>Chenard-Neu</surname><given-names>MP</given-names></name><name><surname>Jaeck</surname><given-names>D</given-names></name></person-group><article-title>Is a proliferation index of cancer cells a reliable prognostic factor after hepatectomy in patients with colorectal liver metastases?</article-title><source>Am J Surg</source><year>2001</year><volume>182</volume><issue>1</issue><fpage>81</fpage><lpage>88</lpage><?supplied-pmid 11532423?><pub-id pub-id-type="pmid">11532423</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xi</surname><given-names>HQ</given-names></name><name><surname>Zhao</surname><given-names>P</given-names></name></person-group><article-title>Clinicopathological significance and prognostic value of EphA3 and CD133 expression in colorectal carcinoma</article-title><source>J Clin Pathol</source><year>2011</year><volume>64</volume><issue>6</issue><fpage>498</fpage><lpage>503</lpage><?supplied-pmid 21415057?><pub-id pub-id-type="pmid">21415057</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ivanecz</surname><given-names>A</given-names></name><name><surname>Kavalar</surname><given-names>R</given-names></name><name><surname>Palfy</surname><given-names>M</given-names></name><name><surname>Pivec</surname><given-names>V</given-names></name><name><surname>Sremec</surname><given-names>M</given-names></name><name><surname>Horvat</surname><given-names>M</given-names></name><name><surname>Potrc</surname><given-names>S</given-names></name></person-group><article-title>Can we improve the clinical risk score? The prognostic value of p53, Ki-67 and thymidylate synthase in patients undergoing radical resection of colorectal liver metastases</article-title><source>HPB (Oxford)</source><year>2014</year><volume>16</volume><issue>3</issue><fpage>235</fpage><lpage>242</lpage><pub-id pub-id-type="pmid">23509992</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosati</surname><given-names>G</given-names></name><name><surname>Chiacchio</surname><given-names>R</given-names></name><name><surname>Reggiardo</surname><given-names>G</given-names></name><name><surname>De Sanctis</surname><given-names>D</given-names></name><name><surname>Manzione</surname><given-names>L</given-names></name></person-group><article-title>Thymidylate synthase expression, p53, bcl-2, Ki-67 and p27 in colorectal cancer: relationships with tumor recurrence and survival</article-title><source>Tumour Biol</source><year>2004</year><volume>25</volume><issue>5&#x02013;6</issue><fpage>258</fpage><lpage>263</lpage><?supplied-pmid 15627889?><pub-id pub-id-type="pmid">15627889</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nishihara</surname><given-names>K</given-names></name><name><surname>Shomori</surname><given-names>K</given-names></name><name><surname>Tamura</surname><given-names>T</given-names></name><name><surname>Fujioka</surname><given-names>S</given-names></name><name><surname>Ogawa</surname><given-names>T</given-names></name><name><surname>Ito</surname><given-names>H</given-names></name></person-group><article-title>Immunohistochemical expression of geminin in colorectal cancer: implication of prognostic significance</article-title><source>Oncol Rep</source><year>2009</year><volume>21</volume><issue>5</issue><fpage>1189</fpage><lpage>1195</lpage><?supplied-pmid 19360293?><pub-id pub-id-type="pmid">19360293</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scopa</surname><given-names>CD</given-names></name><name><surname>Tsamandas</surname><given-names>AC</given-names></name><name><surname>Zolota</surname><given-names>V</given-names></name><name><surname>Kalofonos</surname><given-names>HP</given-names></name><name><surname>Batistatou</surname><given-names>A</given-names></name><name><surname>Vagianos</surname><given-names>C</given-names></name></person-group><article-title>Potential role of bcl-2 and ki-67 expression and apoptosis in colorectal carcinoma: a clinicopathologic study</article-title><source>Dig Dis Sci</source><year>2003</year><volume>48</volume><issue>10</issue><fpage>1990</fpage><lpage>1997</lpage><?supplied-pmid 14627346?><pub-id pub-id-type="pmid">14627346</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Visca</surname><given-names>P</given-names></name><name><surname>Alo</surname><given-names>PL</given-names></name><name><surname>Del</surname><given-names>NF</given-names></name><name><surname>Botti</surname><given-names>C</given-names></name><name><surname>Trombetta</surname><given-names>G</given-names></name><name><surname>Marandino</surname><given-names>F</given-names></name><name><surname>Filippi</surname><given-names>S</given-names></name><name><surname>Di Tondo</surname><given-names>U</given-names></name><name><surname>Donnorso</surname><given-names>RP</given-names></name></person-group><article-title>Immunohistochemical expression of fatty acid synthase, apoptotic-regulating genes, proliferating factors, and ras protein product in colorectal adenomas, carcinomas, and adjacent nonneoplastic mucosa</article-title><source>Clin Cancer Res</source><year>1999</year><volume>5</volume><issue>12</issue><fpage>4111</fpage><lpage>4118</lpage><?supplied-pmid 10632348?><pub-id pub-id-type="pmid">10632348</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Handa</surname><given-names>K</given-names></name><name><surname>Yamakawa</surname><given-names>M</given-names></name><name><surname>Takeda</surname><given-names>H</given-names></name><name><surname>Kimura</surname><given-names>S</given-names></name><name><surname>Takahashi</surname><given-names>T</given-names></name></person-group><article-title>Expression of cell cycle markers in colorectal carcinoma: superiority of cyclin a as an indicator of poor prognosis</article-title><source>Int J Cancer</source><year>1999</year><volume>84</volume><issue>3</issue><fpage>225</fpage><lpage>233</lpage><pub-id pub-id-type="pmid">10371338</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bahnassy</surname><given-names>AA</given-names></name><name><surname>Zekri</surname><given-names>AR</given-names></name><name><surname>El-Houssini</surname><given-names>S</given-names></name><name><surname>El-Shehaby</surname><given-names>AM</given-names></name><name><surname>Mahmoud</surname><given-names>MR</given-names></name><name><surname>Abdallah</surname><given-names>S</given-names></name><name><surname>El-Serafi</surname><given-names>M</given-names></name></person-group><article-title>Cyclin A and cyclin D1 as significant prognostic markers in colorectal cancer patients</article-title><source>BMC Gastroenterol</source><year>2004</year><volume>4</volume><fpage>22</fpage><?supplied-pmid 15385053?><pub-id pub-id-type="pmid">15385053</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buglioni</surname><given-names>S</given-names></name><name><surname>D'Agnano</surname><given-names>I</given-names></name><name><surname>Cosimelli</surname><given-names>M</given-names></name><name><surname>Vasselli</surname><given-names>S</given-names></name><name><surname>D'Angelo</surname><given-names>C</given-names></name><name><surname>Tedesco</surname><given-names>M</given-names></name><name><surname>Zupi</surname><given-names>G</given-names></name><name><surname>Mottolese</surname><given-names>M</given-names></name></person-group><article-title>Evaluation of multiple bio-pathological factors in colorectal adenocarcinomas: independent prognostic role of p53 and bcl-2</article-title><source>Int J Cancer</source><year>1999</year><volume>84</volume><issue>6</issue><fpage>545</fpage><lpage>552</lpage><?supplied-pmid 10567896?><pub-id pub-id-type="pmid">10567896</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bertolini</surname><given-names>F</given-names></name><name><surname>Bengala</surname><given-names>C</given-names></name><name><surname>Losi</surname><given-names>L</given-names></name><name><surname>Pagano</surname><given-names>M</given-names></name><name><surname>Iachetta</surname><given-names>F</given-names></name><name><surname>Dealis</surname><given-names>C</given-names></name><name><surname>Jovic</surname><given-names>G</given-names></name><name><surname>Depenni</surname><given-names>R</given-names></name><name><surname>Zironi</surname><given-names>S</given-names></name><name><surname>Falchi</surname><given-names>AM</given-names></name><etal/></person-group><article-title>Prognostic and predictive value of baseline and posttreatment molecular marker expression in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2007</year><volume>68</volume><issue>5</issue><fpage>1455</fpage><lpage>1461</lpage><?supplied-pmid 17445998?><pub-id pub-id-type="pmid">17445998</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kimura</surname><given-names>T</given-names></name><name><surname>Tanaka</surname><given-names>S</given-names></name><name><surname>Haruma</surname><given-names>K</given-names></name><name><surname>Sumii</surname><given-names>K</given-names></name><name><surname>Kajiyama</surname><given-names>G</given-names></name><name><surname>Shimamoto</surname><given-names>F</given-names></name><name><surname>Kohon</surname><given-names>N</given-names></name></person-group><article-title>Clinical significance of MUC1 and E-cadherin expression, cellular proliferation, and angiogenesis at the deepest invasive portion of colorectal cancer</article-title><source>Int J Oncol</source><year>2000</year><volume>16</volume><issue>1</issue><fpage>55</fpage><lpage>64</lpage><?supplied-pmid 10601549?><pub-id pub-id-type="pmid">10601549</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fernandez-Cebrian</surname><given-names>JM</given-names></name><name><surname>Nevado</surname><given-names>SM</given-names></name><name><surname>Vorwald</surname><given-names>KP</given-names></name><name><surname>Pardo</surname><given-names>DLM</given-names></name><name><surname>Martin-Cavanna</surname><given-names>J</given-names></name><name><surname>Pacheco</surname><given-names>MP</given-names></name><name><surname>Fern&#x000e1;ndez Escudero</surname><given-names>B</given-names></name><name><surname>Ramos</surname><given-names>FM</given-names></name></person-group><article-title>Can the clinical outcome in stage II colon carcinomas be predicted by determination of molecular marker expression?</article-title><source>Clin Transl Oncol</source><year>2007</year><volume>9</volume><issue>10</issue><fpage>663</fpage><lpage>670</lpage><?supplied-pmid 17974527?><pub-id pub-id-type="pmid">17974527</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>XS</given-names></name><name><surname>Xi</surname><given-names>HQ</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name></person-group><article-title>Lgr5 is a potential marker of colorectal carcinoma stem cells that correlates with patient survival</article-title><source>World J Surg Oncol</source><year>2012</year><volume>10</volume><fpage>244</fpage><?supplied-pmid 23153436?><pub-id pub-id-type="pmid">23153436</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Furudoi</surname><given-names>A</given-names></name><name><surname>Tanaka</surname><given-names>S</given-names></name><name><surname>Haruma</surname><given-names>K</given-names></name><name><surname>Yoshihara</surname><given-names>M</given-names></name><name><surname>Sumii</surname><given-names>K</given-names></name><name><surname>Kajiyama</surname><given-names>G</given-names></name><name><surname>Shimamoto</surname><given-names>F</given-names></name></person-group><article-title>Clinical significance of human erythrocyte glucose transporter 1 expression at the deepest invasive site of advanced colorectal carcinoma</article-title><source>Oncology</source><year>2001</year><volume>60</volume><issue>2</issue><fpage>162</fpage><lpage>169</lpage><?supplied-pmid 11244332?><pub-id pub-id-type="pmid">11244332</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>MX</given-names></name><name><surname>Wen</surname><given-names>ZF</given-names></name><name><surname>Feng</surname><given-names>ZY</given-names></name><name><surname>He</surname><given-names>D</given-names></name></person-group><article-title>Expression and significance of Bmi-1 and Ki67 in colorectal carcinoma tissues</article-title><source>Ai Zheng</source><year>2008</year><volume>27</volume><issue>12</issue><fpage>1321</fpage><lpage>1326</lpage><?supplied-pmid 19080002?><pub-id pub-id-type="pmid">19080002</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hayashi</surname><given-names>H</given-names></name><name><surname>Beppu</surname><given-names>T</given-names></name><name><surname>Sakamoto</surname><given-names>Y</given-names></name><name><surname>Miyamoto</surname><given-names>Y</given-names></name><name><surname>Yokoyama</surname><given-names>N</given-names></name><name><surname>Higashi</surname><given-names>T</given-names></name><name><surname>Nitta</surname><given-names>H</given-names></name><name><surname>Hashimoto</surname><given-names>D</given-names></name><name><surname>Chikamoto</surname><given-names>A</given-names></name><name><surname>Baba</surname><given-names>H</given-names></name></person-group><article-title>Prognostic value of Ki-67 expression in conversion therapy for colorectal liver-limited metastases</article-title><source>Am J Cancer Res</source><year>2015</year><volume>5</volume><issue>3</issue><fpage>1225</fpage><lpage>1233</lpage><?supplied-pmid 26046001?><pub-id pub-id-type="pmid">26046001</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ajani</surname><given-names>JA</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Izzo</surname><given-names>JG</given-names></name><name><surname>Crane</surname><given-names>CH</given-names></name><name><surname>Eng</surname><given-names>C</given-names></name><name><surname>Skibber</surname><given-names>JM</given-names></name><name><surname>Das</surname><given-names>P</given-names></name><name><surname>Rashid</surname><given-names>A</given-names></name></person-group><article-title>Molecular biomarkers correlate with disease-free survival in patients with anal canal carcinoma treated with chemoradiation</article-title><source>Dig Dis Sci</source><year>2010</year><volume>55</volume><issue>4</issue><fpage>98</fpage><lpage>105</lpage></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>D</given-names></name><name><surname>Yan</surname><given-names>D</given-names></name><name><surname>Tang</surname><given-names>H</given-names></name><name><surname>Zhou</surname><given-names>C</given-names></name><name><surname>Fan</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Xia</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>F</given-names></name><name><surname>Qiu</surname><given-names>G</given-names></name><etal/></person-group><article-title>IMP3 is a novel prognostic marker that correlates with colon cancer progression and pathogenesis</article-title><source>Ann Surg Oncol</source><year>2009</year><volume>16</volume><issue>12</issue><fpage>3499</fpage><lpage>3506</lpage><?supplied-pmid 19672661?><pub-id pub-id-type="pmid">19672661</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>TH</given-names></name><name><surname>Lin</surname><given-names>JW</given-names></name><name><surname>Chen</surname><given-names>HH</given-names></name><name><surname>Liu</surname><given-names>LF</given-names></name><name><surname>Chuah</surname><given-names>SK</given-names></name><name><surname>Tai</surname><given-names>MH</given-names></name></person-group><article-title>The expression and prognostic role of hepatoma-derived growth factor in colorectal stromal tumors</article-title><source>Dis Colon Rectum</source><year>2009</year><volume>52</volume><issue>2</issue><fpage>319</fpage><lpage>326</lpage><?supplied-pmid 19279430?><pub-id pub-id-type="pmid">19279430</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roxburgh</surname><given-names>CS</given-names></name><name><surname>Richards</surname><given-names>CH</given-names></name><name><surname>Macdonald</surname><given-names>AI</given-names></name><name><surname>Powell</surname><given-names>AG</given-names></name><name><surname>McGlynn</surname><given-names>LM</given-names></name><name><surname>McMillan</surname><given-names>DC</given-names></name><name><surname>Horgan</surname><given-names>PG</given-names></name><name><surname>Edwards</surname><given-names>J</given-names></name><name><surname>Shiels</surname><given-names>PG</given-names></name></person-group><article-title>The in situ local immune response, tumour senescence and proliferation in colorectal cancer</article-title><source>Br J Cancer</source><year>2013</year><volume>109</volume><issue>8</issue><fpage>2207</fpage><lpage>2216</lpage><?supplied-pmid 24022192?><pub-id pub-id-type="pmid">24022192</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shin</surname><given-names>IY</given-names></name><name><surname>Sung</surname><given-names>NY</given-names></name><name><surname>Lee</surname><given-names>YS</given-names></name><name><surname>Kwon</surname><given-names>TS</given-names></name><name><surname>Si</surname><given-names>Y</given-names></name><name><surname>Lee</surname><given-names>YS</given-names></name><name><surname>Oh</surname><given-names>ST</given-names></name><name><surname>Lee</surname><given-names>IK</given-names></name></person-group><article-title>The expression of multiple proteins as prognostic factors in colorectal cancer: cathepsin D, p53, COX-2, epidermal growth factor receptor, C-erbB-2, and Ki-67</article-title><source>Gut Liver</source><year>2014</year><volume>8</volume><issue>1</issue><fpage>13</fpage><lpage>23</lpage><?supplied-pmid 24516696?><pub-id pub-id-type="pmid">24516696</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nash</surname><given-names>GM</given-names></name><name><surname>Gimbel</surname><given-names>M</given-names></name><name><surname>Shia</surname><given-names>J</given-names></name><name><surname>Nathanson</surname><given-names>DR</given-names></name><name><surname>Ndubuisi</surname><given-names>MI</given-names></name><name><surname>Zeng</surname><given-names>ZS</given-names></name><name><surname>Kemeny</surname><given-names>N</given-names></name><name><surname>Paty</surname><given-names>PB</given-names></name></person-group><article-title>KRAS mutation correlates with accelerated metastatic progression in patients with colorectal liver metastases</article-title><source>Ann Surg Oncol</source><year>2010</year><volume>17</volume><issue>2</issue><fpage>572</fpage><lpage>578</lpage><?supplied-pmid 19727962?><pub-id pub-id-type="pmid">19727962</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prall</surname><given-names>F</given-names></name><name><surname>Ostwald</surname><given-names>C</given-names></name><name><surname>Nizze</surname><given-names>H</given-names></name><name><surname>Barten</surname><given-names>M</given-names></name></person-group><article-title>Expression profiling of colorectal carcinomas using tissue microarrays: cell cycle regulatory proteins p21, p27, and p53 as immunohistochemical prognostic markers in univariate and multivariate analysis</article-title><source>Appl Immunohistochem Mol Morphol</source><year>2004</year><volume>12</volume><issue>2</issue><fpage>111</fpage><lpage>121</lpage><?supplied-pmid 15354735?><pub-id pub-id-type="pmid">15354735</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zlobec</surname><given-names>I</given-names></name><name><surname>Baker</surname><given-names>K</given-names></name><name><surname>Terracciano</surname><given-names>L</given-names></name><name><surname>Peter</surname><given-names>S</given-names></name><name><surname>Degen</surname><given-names>L</given-names></name><name><surname>Beglinger</surname><given-names>C</given-names></name><name><surname>Lugli</surname><given-names>A</given-names></name></person-group><article-title>Two-marker protein profile predicts poor prognosis in patients with early rectal cancer</article-title><source>Br J Cancer</source><year>2008</year><volume>99</volume><issue>10</issue><fpage>1712</fpage><lpage>1717</lpage><?supplied-pmid 18985041?><pub-id pub-id-type="pmid">18985041</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stroup</surname><given-names>DF</given-names></name><name><surname>Berlin</surname><given-names>JA</given-names></name><name><surname>Morton</surname><given-names>SC</given-names></name><name><surname>Williamson</surname><given-names>GD</given-names></name><name><surname>Rennie</surname><given-names>D</given-names></name><name><surname>Moher</surname><given-names>D</given-names></name><name><surname>Moher</surname><given-names>D</given-names></name><name><surname>Becker</surname><given-names>BJ</given-names></name><name><surname>Sipe</surname><given-names>TA</given-names></name><name><surname>Thacker</surname><given-names>SB</given-names></name></person-group><article-title>Meta analysis of observational studies in epidemiology: a proposal for reporting. Metaanalysis Of Observational Studies in Epidemiology (MOOSE) group</article-title><source>JAMA</source><year>2000</year><volume>283</volume><fpage>2008</fpage><lpage>2012</lpage><?supplied-pmid 10789670?><pub-id pub-id-type="pmid">10789670</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peters</surname><given-names>JL</given-names></name><name><surname>Sutton</surname><given-names>AJ</given-names></name><name><surname>Jones</surname><given-names>DR</given-names></name><name><surname>Abrams</surname><given-names>KR</given-names></name><name><surname>Rushton</surname><given-names>L</given-names></name></person-group><article-title>Contour-enhanced meta analysis funnel plots help distinguish publication bias from other causes of asymmetry</article-title><source>J Clin Epidemiol</source><year>2008</year><volume>61</volume><fpage>991</fpage><lpage>996</lpage><?supplied-pmid 18538991?><pub-id pub-id-type="pmid">18538991</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pollack</surname><given-names>A</given-names></name><name><surname>DeSilvio</surname><given-names>M</given-names></name><name><surname>Khor</surname><given-names>LY</given-names></name><name><surname>Li</surname><given-names>R</given-names></name><name><surname>Al-Saleem</surname><given-names>TI</given-names></name><name><surname>Hammond</surname><given-names>ME</given-names></name><name><surname>Venkatesan</surname><given-names>V</given-names></name><name><surname>Lawton</surname><given-names>CA</given-names></name><name><surname>Roach</surname><given-names>M</given-names><suffix>3rd</suffix></name><name><surname>Shipley</surname><given-names>WU</given-names></name><etal/></person-group><article-title>Ki-67 staining is a strong predictor of distant metastasis and mortality for men with prostate cancer treated with radiotherapy and androgen deprivation: Radiation Therapy Oncology Group Trial 92&#x02013;02</article-title><source>J Clin Oncol</source><year>2004</year><volume>22</volume><fpage>2133</fpage><lpage>2140</lpage><?supplied-pmid 15169799?><pub-id pub-id-type="pmid">15169799</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bui</surname><given-names>MH</given-names></name><name><surname>Visapaa</surname><given-names>H</given-names></name><name><surname>Seligson</surname><given-names>D</given-names></name><name><surname>Kim</surname><given-names>H</given-names></name><name><surname>Han</surname><given-names>KR</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Horvath</surname><given-names>S</given-names></name><name><surname>Stanbridge</surname><given-names>EJ</given-names></name><name><surname>Palotie</surname><given-names>A</given-names></name><name><surname>Figlin</surname><given-names>RA</given-names></name><etal/></person-group><article-title>Prognostic value of kroniek anhydrase IX and Ki67 as predictor of survival for renal clear cell cancer</article-title><source>J Urol</source><year>2004</year><volume>171</volume><fpage>2461</fpage><lpage>2466</lpage><?supplied-pmid 15126876?><pub-id pub-id-type="pmid">15126876</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tisell</surname><given-names>LE</given-names></name><name><surname>Oden</surname><given-names>A</given-names></name><name><surname>Muth</surname><given-names>A</given-names></name><name><surname>Altiparmak</surname><given-names>G</given-names></name><name><surname>Molne</surname><given-names>J</given-names></name><name><surname>Ahlman</surname><given-names>H</given-names></name><name><surname>Nilsson</surname><given-names>O</given-names></name></person-group><article-title>The Ki67 index a prognostic marker in medullary thyroid carcinoma</article-title><source>Br J Cancer</source><year>2003</year><volume>89</volume><fpage>2093</fpage><lpage>2097</lpage><?supplied-pmid 14647143?><pub-id pub-id-type="pmid">14647143</pub-id></element-citation></ref></ref-list></back></article>